bioreference patient login

How do I view my BioReference test results?

View your BioReference test results in the Apple Health app on iPhone* or CommonHealth app on Android devices. It’s easy to view your laboratory test results in the same place as your other important health information. Learn how to get started today.

Why choose BioReference for prostate cancer diagnostics?

From clinical routine to esoteric assays, BioReference’s expansive test menu aids healthcare providers in the diagnosis, monitoring and treatment of disease for their patients. The 4Kscore® Test helps clarify the biopsy decision-making process by determining a patient-specific probability for finding aggressive prostate cancer.

What should I do if I am experiencing issues with patient portal?

If you are experiencing patient portal issues related to identity verification or login, please call us at 1-888-279-0967 M-F 8AM-8PM ET and Sa-Su 9AM-5PM ET or send an email to patientportal@bioreference.com with your name and phone number, and we will get back to you as soon as possible.

The laboratory at your fingertips

BioReference is empowering patients with knowledge to enhance engagement in their healthcare journey through digitally enabled, secure, and on-demand solutions.

COVID-19 Game Plan

The days are getting shorter, there is a cool crisp in the air, and the leaves are changing colors; it’s undoubtedly fall. The return of the autumnal season also means football has kicked-off, baseball playoffs are here, basketball is just beginning, hockey players are ready to hit the ice, and soccer teams have rivalry match-ups.

NBA to primarily use rapid tests for COVID-19 in 2021-22

Given the league’s high vaccination rate, the NBA’s primary form of COVID-19 detection this season will center on designated team officials — largely members of the medical staff — using small, at-home, molecular-based testing devices that can return results in 20 minutes.

Gynecological Cancer Awareness Month

Gynecologic Cancer Awareness Month is an opportunity to raise awareness of the different types of cancers that originate in a woman’s reproductive organs.Each year, about 94,000 women are diagnosed with gynecologic cancer so it is important to understand the risk factors and possible symptoms along with available treatment options.

In JAMA Oncology Publication, GeneDx Describes Lower Lifetime Risk of Gastric Cancer Conferred by CDH1

Updated Cancer Risk Estimates Will Allow For More Personalized Risk Assessment and Informed Decision Making For Patients with Rare Form of Hereditary Stomach Cancer GAITHERSBURG, Md., Aug.